[Home ] [Archive]   [ فارسی ]  
Main Menu
Home::
Journal Information::
Archive ::
For Authors::
For Reviewers::
Ethical Code::
Subscription::
Contact us::
Peer Review Process::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 7 - ::
Ir J Physiol Pharmacol 2023, 7 - : 197-205 Back to browse issues page
Preparation of Polyclonal Antibody against B-cell activating factor
Rasoul Mardani-Jouneghani , Shiva Irani , Mahdi Habibi-Anbouhi , Mahdi Behdani *
Biotechnology Research Centre, Venom and Biotherapeutics Molecules Laboratory, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (429 Views)
Background and Aim: B-cell activating factor (BAFF) belongs to the tumor necrosis factor (TNF) superfamily and plays a critical role in B-cell survival and differentiation. Overexpression of BAFF has been linked to autoimmune diseases and B-cell malignancies. The biologically active segment of this protein is a soluble domain, making it a promising target for antibody-based therapies. This study aimed to develop a polyclonal camel antibody capable of detecting BAFF on cell surfaces.
Methods: An expression vector, pET22b, containing the extracellular domain of the BAFF protein (NM_001145645.2), was constructed and introduced into Escherichia coli BL21 (DE3) using the calcium chloride heat shock method (CaCl2). Subsequently, the recombinant protein was induced using 1mM IPTG and protein purification was carried out with Ni2+–NTA resin. A 9-month-old female Camelus dromedaries was immunized with purified recombinant BAFF protein (rBAFF) mixed with Freund's adjuvant. Following immunization, the isolated polyclonal antibody was assessed using ELISA, western blotting, and flow cytometry to detect rBAFF protein.
Results: The study confirmed the successful preparation of recombinant BAFF protein and the effectiveness of camel immunization and purification processes. The isolated polyclonal antibody demonstrated the ability to identify recombinant BAFF proteins in ELISA and western blot tests. Flow cytometry demonstrated its capacity to detect BAFF protein on cell surfaces.
Conclusion: Given the significance of diagnosing and developing novel adjuvant treatment methods for autoimmune diseases and cancer, this study's findings support the potential use of polyclonal antibodies targeting the BAFF antigen as valuable tools for these purposes.
Keywords: B-cell activating factor, Camel, Heavy chain antibody, Polyclonal antibody
Full-Text [PDF 1713 kb]   (277 Downloads)    
Type of Study: Original Research | Subject: Others...
Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mardani-Jouneghani R, Irani S, Habibi-Anbouhi M, Behdani M. Preparation of Polyclonal Antibody against B-cell activating factor. Ir J Physiol Pharmacol 2023; 7 :197-205
URL: http://ijpp.phypha.ir/article-1-674-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 7 - Back to browse issues page
مجله فیزیولوژی و فارماکولوژی ایران Iranian Journal of Physiology and Pharmacology
Persian site map - English site map - Created in 0.05 seconds with 36 queries by YEKTAWEB 4710